Gary Altman, PhD


Gary is an experienced leader of buy-side and sell-side transactions in life science companies. He is a serial entrepreneur and has held multiple CEO roles. Gary founded, led, and divested companies. At Beckman Coulter he led global market and business development for the $1B Cellular Analysis Business Group.

Ned Waller, MD PhD

Scientific Founder & Chairman
Scientific Advisor, Board Member

Ned received his A.B. from Harvard, a Ph.D. from Rockefeller University, and an M.D. from Cornell University. He completed his Internal Medicine residency and Medical Oncology Fellowship at Stanford and post-doctoral training with Dr. Irv Weissman, focusing on human T-cell development. He has had various leadership roles at Emory University including the Associate Director of Clinical Research for the Winship Cancer Institute, Director of Regenerative Engineering and Medicine, and holds the Rein Saral Professorship in Cancer Medicine. He has built an R01-funded research program in translational and clinical research in cancer immunology. Dr. Waller is a clinician scientist entrepreneur and co-founded Cambium Oncology, a pre-clinical start-up, to develop a novel immune checkpoint drug targeting the receptor for vasoactive intestinal peptide. He serves as the Editor for ImmunoMedicine and chairs the Translational Immuno-Oncology (TIO) study section at the NIH.

Giovanni Selvaggi, MD

Medical Advisor, Board Member

Experienced early/late stage clinical developer based in US with 10+ years of pharmaceutical industry in oncology.Academic and clinical skills in thoracic oncology, Medical Doctor/pulmonologist @Università di Torino in Italy.

Taofeek Owonikoko, MD PhD

Scientific Advisor, Board Member

The main goal for our translational research work is to develop new treatment options for patients with lung cancer and cancer of the thyroid and head and neck. The laboratory effort in this area is focused on understanding the role of immune function in thyroid cancer biology and patient outcome. Our lab also conducts early preclinical and animal studies to explore the efficacy of biologic agents including mTOR inhibitors, PARP inhibitors, Polo like kinase 1 inhibitors and epigenetic targeted therapy.

The result of this preclinical work serve as preliminary evidence of anticancer efficacy that support subsequent testing of the same treatment concept in human subjects. Using this approach, we have successfully advanced several anticancer agents and drug combination from the lab to the clinic using institutional investigator-sponsored trials as well as national cooperative group phase I and phase II clinical trials as vehicle of anticancer drug development.

Terry Walts, MBA

Board Member